Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight‐loss outcomes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To identify an early treatment milestone that optimizes sensitivity and specificity for predicting ≥5% weight loss at Week (W) 52 in patients with and without type 2 diabetes on lorcaserin or placebo. METHODS: Post hoc area under the curve for receiver operating characteristic analyses of data from three phase 3 trials comparing lifestyle modification+placebo with lifestyle modification+lorcaserin. A total of 6897 patients (18-65 years; BMI, 30-45 or 27-29.9 kg/m(2) with ≥1 comorbidity) were randomized to placebo or lorcaserin 10 mg bid. Changes (baseline to W52) in cardiometabolic parameters were assessed. RESULTS: Response (≥5% weight loss from baseline) at W12 was a strong predictor of W52 response. Lorcaserin patients with a W12 response achieved mean W52 weight losses of 10.6 kg (without diabetes) and 9.3 kg (with diabetes). Proportions achieving ≥5% and ≥10% weight loss at W52 were 85.5% and 49.8% (without diabetes), and 70.5% and 35.9% (with diabetes). Lorcaserin patients who did not achieve a W12 response lost 3.2 kg (without diabetes) and 2.8 kg (with diabetes) at W52. Responders had greater improvements in cardiometabolic risk factors than the modified intent-to-treat (MITT) population, consistent with greater weight loss. CONCLUSIONS: ≥5% weight loss by W12 predicts robust response to lorcaserin at 1 year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“diabetes (9-11), arthritis (12,13), and risk of disability (11).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 2×
“diabetes (9-11), arthritis (12,13), and risk of disability (11).”
BackgroundValvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Elfhag, K., & Rössner, S. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00170.x · Cited by 1,343 · cited 1×
“In addition to these metabolic benefits, early response to weight-loss interventions is a key motivator for continuing therapy and maintaining weight loss (31).”
BackgroundEffect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“Several studies have shown that the loss of 5–10% of body weight can benefit hypertension, dyslipidemia, type 2 diabetes, and arthritis (4,8,10,13) and can also help prevent the development of type 2 diabetes (11,29,30).”
BackgroundSelf-citationMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 2×
“The efficacy and safety of lorcaserin 10 mg bid has been evaluated in three phase 3 clinical studies in adult populations with and without type 2 diabetes: Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM; N 5 3182) (25), Behavioral Modification and Lorcaserin Second Study of Obesity…”
BackgroundMethodSelf-citation
Cited by
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Fujioka, K., O'Neil, P. M., Davies, M., Greenway, F., C.W. Lau, D., Claudius, B., Skjøth, T. V., Bjørn Jensen, C., & P.H. Wilding, J. (2016) · Obesity · doi:10.1002/oby.21629 · Cited by 131
“Early weight loss, whether through lifestyle (4-7) or pharmacotherapy (8-11), is a good predictor of long-term weight loss.”
BackgroundSelf-citationGoldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Precision medicine in adult and pediatric obesity: a clinical perspective
Bomberg, E. M., Ryder, J. R., Brundage, R. C., Straka, R. J., Fox, C. K., Gross, A. C., Oberle, M. M., Bramante, C. T., Sibley, S. D., & Kelly, A. S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863022 · Cited by 52
The Benefit of Short-Term Weight Loss with Anti-Obesity Medications in Real-World Clinical Practice
Shibuya, K., Ali, K. F., Ji, X., Milinoivh, A., Bauman, J., Kattan, M. W., Pantalone, K. M., & Burguera, B. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0081 · Cited by 27
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
Lee, S. E., Lee, N. Y., Kim, S. H., Kim, K.-A., & Kim, Y. S. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113830 · Cited by 27
Potential contributors to variation in weight‐loss response to liraglutide
Webster, C. M., Mittal, N., Dhurandhar, E. J., & Dhurandhar, N. V. (2023) · Obesity Reviews · doi:10.1111/obr.13568 · Cited by 19
Metadata
- Authors
- Smith, S. R., O'Neil, P. M., Astrup, A., Finer, N., Sanchez‐Kam, M., Fraher, K., Fain, R., & Shanahan, W. R.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2014-07-18
- Volume
- 22
- Issue
- 10
- Pages
- 2137-2146
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W1511363514
- Cited by
- 49
- References
- 9
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.